Skip to main content
NCBI home page
Gut logoLink to Gut
. 1999 Jan;44(1):137–142. doi: 10.1136/gut.44.1.137

Oral tolerance in disease

P GARSIDE 1, A MOWAT 1, A KHORUTS 1
PMCID: PMC1760052  PMID: 9862840

Full Text

The Full Text of this article is available as a PDF (118.7 KB).

Figure 1 .

Figure 1

Open in a new tab

Relation between infection, immunoregulation, barrier function, and inflammation. 


Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aroeira L. S., Cardillo F., De Albuquerque D. A., Vaz N. M., Mengel J. Anti-IL-10 treatment does not block either the induction or the maintenance of orally induced tolerance to OVA. Scand J Immunol. 1995 Apr;41(4):319–323. doi: 10.1111/j.1365-3083.1995.tb03573.x. [DOI] [PubMed] [Google Scholar]
  2. Baribault H., Penner J., Iozzo R. V., Wilson-Heiner M. Colorectal hyperplasia and inflammation in keratin 8-deficient FVB/N mice. Genes Dev. 1994 Dec 15;8(24):2964–2973. doi: 10.1101/gad.8.24.2964. [DOI] [PubMed] [Google Scholar]
  3. Barnett M. L., Combitchi D., Trentham D. E. A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis. Arthritis Rheum. 1996 Apr;39(4):623–628. doi: 10.1002/art.1780390413. [DOI] [PubMed] [Google Scholar]
  4. Barone K. S., Jain S. L., Michael J. G. Effect of in vivo depletion of CD4+ and CD8+ cells on the induction and maintenance of oral tolerance. Cell Immunol. 1995 Jun;163(1):19–29. doi: 10.1006/cimm.1995.1094. [DOI] [PubMed] [Google Scholar]
  5. Baschieri S., Lees R. K., Lussow A. R., MacDonald H. R. Clonal anergy to staphylococcal enterotoxin B in vivo: selective effects on T cell subsets and lymphokines. Eur J Immunol. 1993 Oct;23(10):2661–2666. doi: 10.1002/eji.1830231041. [DOI] [PubMed] [Google Scholar]
  6. Bergerot I., Fabien N., Maguer V., Thivolet C. Oral administration of human insulin to NOD mice generates CD4+ T cells that suppress adoptive transfer of diabetes. J Autoimmun. 1994 Oct;7(5):655–663. doi: 10.1006/jaut.1994.1050. [DOI] [PubMed] [Google Scholar]
  7. Bergerot I., Ploix C., Petersen J., Moulin V., Rask C., Fabien N., Lindblad M., Mayer A., Czerkinsky C., Holmgren J. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4610–4614. doi: 10.1073/pnas.94.9.4610. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Bitar D. M., Whitacre C. C. Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein. Cell Immunol. 1988 Apr 1;112(2):364–370. doi: 10.1016/0008-8749(88)90305-x. [DOI] [PubMed] [Google Scholar]
  9. Blanas E., Carbone F. R., Allison J., Miller J. F., Heath W. R. Induction of autoimmune diabetes by oral administration of autoantigen. Science. 1996 Dec 6;274(5293):1707–1709. doi: 10.1126/science.274.5293.1707. [DOI] [PubMed] [Google Scholar]
  10. Boismenu R., Havran W. L. Modulation of epithelial cell growth by intraepithelial gamma delta T cells. Science. 1994 Nov 18;266(5188):1253–1255. doi: 10.1126/science.7973709. [DOI] [PubMed] [Google Scholar]
  11. Chen Y., Inobe J., Kuchroo V. K., Baron J. L., Janeway C. A., Jr, Weiner H. L. Oral tolerance in myelin basic protein T-cell receptor transgenic mice: suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells. Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):388–391. doi: 10.1073/pnas.93.1.388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Chen Y., Inobe J., Marks R., Gonnella P., Kuchroo V. K., Weiner H. L. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature. 1995 Jul 13;376(6536):177–180. doi: 10.1038/376177a0. [DOI] [PubMed] [Google Scholar]
  13. Chen Y., Inobe J., Weiner H. L. Induction of oral tolerance to myelin basic protein in CD8-depleted mice: both CD4+ and CD8+ cells mediate active suppression. J Immunol. 1995 Jul 15;155(2):910–916. [PubMed] [Google Scholar]
  14. Chen Y., Inobe J., Weiner H. L. Inductive events in oral tolerance in the TCR transgenic adoptive transfer model. Cell Immunol. 1997 May 25;178(1):62–68. doi: 10.1006/cimm.1997.1119. [DOI] [PubMed] [Google Scholar]
  15. Chen Y., Kuchroo V. K., Inobe J., Hafler D. A., Weiner H. L. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science. 1994 Aug 26;265(5176):1237–1240. doi: 10.1126/science.7520605. [DOI] [PubMed] [Google Scholar]
  16. DRESSER D. W. Effectiveness of lipid and lipidophilic substances as adjuvants. Nature. 1961 Sep 16;191:1169–1171. doi: 10.1038/1911169a0. [DOI] [PubMed] [Google Scholar]
  17. Desvignes C., Bour H., Nicolas J. F., Kaiserlian D. Lack of oral tolerance but oral priming for contact sensitivity to dinitrofluorobenzene in major histocompatibility complex class II-deficient mice and in CD4+ T cell-depleted mice. Eur J Immunol. 1996 Aug;26(8):1756–1761. doi: 10.1002/eji.1830260814. [DOI] [PubMed] [Google Scholar]
  18. Ding L., Linsley P. S., Huang L. Y., Germain R. N., Shevach E. M. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol. 1993 Aug 1;151(3):1224–1234. [PubMed] [Google Scholar]
  19. Drachman D. B., Okumura S., Adams R. N., McIntosh K. R. Oral tolerance in myasthenia gravis. Ann N Y Acad Sci. 1996 Feb 13;778:258–272. doi: 10.1111/j.1749-6632.1996.tb21134.x. [DOI] [PubMed] [Google Scholar]
  20. Duchmann R., Kaiser I., Hermann E., Mayet W., Ewe K., Meyer zum Büschenfelde K. H. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD) Clin Exp Immunol. 1995 Dec;102(3):448–455. doi: 10.1111/j.1365-2249.1995.tb03836.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Duchmann R., Schmitt E., Knolle P., Meyer zum Büschenfelde K. H., Neurath M. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur J Immunol. 1996 Apr;26(4):934–938. doi: 10.1002/eji.1830260432. [DOI] [PubMed] [Google Scholar]
  22. Elson C. O., Sartor R. B., Tennyson G. S., Riddell R. H. Experimental models of inflammatory bowel disease. Gastroenterology. 1995 Oct;109(4):1344–1367. doi: 10.1016/0016-5085(95)90599-5. [DOI] [PubMed] [Google Scholar]
  23. Fiorentino D. F., Zlotnik A., Vieira P., Mosmann T. R., Howard M., Moore K. W., O'Garra A. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol. 1991 May 15;146(10):3444–3451. [PubMed] [Google Scholar]
  24. Fishman-Lobell J., Friedman A., Weiner H. L. Different kinetic patterns of cytokine gene expression in vivo in orally tolerant mice. Eur J Immunol. 1994 Nov;24(11):2720–2724. doi: 10.1002/eji.1830241122. [DOI] [PubMed] [Google Scholar]
  25. Fukaura H., Kent S. C., Pietrusewicz M. J., Khoury S. J., Weiner H. L., Hafler D. A. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest. 1996 Jul 1;98(1):70–77. doi: 10.1172/JCI118779. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Garside P., Mowat A. M. Mechanisms of oral tolerance. Crit Rev Immunol. 1997;17(2):119–137. doi: 10.1615/critrevimmunol.v17.i2.10. [DOI] [PubMed] [Google Scholar]
  27. Garside P., Steel M., Liew F. Y., Mowat A. M. CD4+ but not CD8+ T cells are required for the induction of oral tolerance. Int Immunol. 1995 Mar;7(3):501–504. doi: 10.1093/intimm/7.3.501. [DOI] [PubMed] [Google Scholar]
  28. Garside P., Steel M., Worthey E. A., Satoskar A., Alexander J., Bluethmann H., Liew F. Y., Mowat A. M. T helper 2 cells are subject to high dose oral tolerance and are not essential for its induction. J Immunol. 1995 Jun 1;154(11):5649–5655. [PubMed] [Google Scholar]
  29. Groux H., O'Garra A., Bigler M., Rouleau M., Antonenko S., de Vries J. E., Roncarolo M. G. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997 Oct 16;389(6652):737–742. doi: 10.1038/39614. [DOI] [PubMed] [Google Scholar]
  30. Guimaraes V. C., Quintans J., Fisfalen M. E., Straus F. H., Wilhelm K., Medeiros-Neto A., DeGroot L. J. Suppression of development of experimental autoimmune thyroiditis by oral administration of thyroglobulin. Endocrinology. 1995 Aug;136(8):3353–3359. doi: 10.1210/endo.136.8.7543043. [DOI] [PubMed] [Google Scholar]
  31. He Y. G., Mellon J., Niederkorn J. Y. The effect of oral immunization on corneal allograft survival. Transplantation. 1996 Mar 27;61(6):920–926. doi: 10.1097/00007890-199603270-00014. [DOI] [PubMed] [Google Scholar]
  32. Hermiston M. L., Gordon J. I. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science. 1995 Nov 17;270(5239):1203–1207. doi: 10.1126/science.270.5239.1203. [DOI] [PubMed] [Google Scholar]
  33. Higgins P. J., Weiner H. L. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments. J Immunol. 1988 Jan 15;140(2):440–445. [PubMed] [Google Scholar]
  34. Hirahara K., Hisatsune T., Nishijima K., Kato H., Shiho O., Kaminogawa S. CD4+ T cells anergized by high dose feeding establish oral tolerance to antibody responses when transferred in SCID and nude mice. J Immunol. 1995 Jun 15;154(12):6238–6245. [PubMed] [Google Scholar]
  35. Husby S., Foged N., Høst A., Svehag S. E. Passage of dietary antigens into the blood of children with coeliac disease. Quantification and size distribution of absorbed antigens. Gut. 1987 Sep;28(9):1062–1072. doi: 10.1136/gut.28.9.1062. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Husby S., Jensenius J. C., Svehag S. E. Passage of undegraded dietary antigen into the blood of healthy adults. Further characterization of the kinetics of uptake and the size distribution of the antigen. Scand J Immunol. 1986 Oct;24(4):447–455. doi: 10.1111/j.1365-3083.1986.tb02133.x. [DOI] [PubMed] [Google Scholar]
  37. Husby S., Mestecky J., Moldoveanu Z., Holland S., Elson C. O. Oral tolerance in humans. T cell but not B cell tolerance after antigen feeding. J Immunol. 1994 May 1;152(9):4663–4670. [PubMed] [Google Scholar]
  38. Jarrett E. E. Perinatal influences on IgE responses. Lancet. 1984 Oct 6;2(8406):797–799. doi: 10.1016/s0140-6736(84)90716-5. [DOI] [PubMed] [Google Scholar]
  39. Ke Y., Kapp J. A. Oral antigen inhibits priming of CD8+ CTL, CD4+ T cells, and antibody responses while activating CD8+ suppressor T cells. J Immunol. 1996 Feb 1;156(3):916–921. [PubMed] [Google Scholar]
  40. Kearney E. R., Pape K. A., Loh D. Y., Jenkins M. K. Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity. 1994 Jul;1(4):327–339. doi: 10.1016/1074-7613(94)90084-1. [DOI] [PubMed] [Google Scholar]
  41. Khoruts A., Miller S. D., Jenkins M. K. Neuroantigen-specific Th2 cells are inefficient suppressors of experimental autoimmune encephalomyelitis induced by effector Th1 cells. J Immunol. 1995 Nov 15;155(10):5011–5017. [PubMed] [Google Scholar]
  42. Khoury S. J., Hancock W. W., Weiner H. L. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. J Exp Med. 1992 Nov 1;176(5):1355–1364. doi: 10.1084/jem.176.5.1355. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Kim P. H., Kagnoff M. F. Transforming growth factor-beta 1 is a costimulator for IgA production. J Immunol. 1990 May 1;144(9):3411–3416. [PubMed] [Google Scholar]
  44. Kühn R., Löhler J., Rennick D., Rajewsky K., Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993 Oct 22;75(2):263–274. doi: 10.1016/0092-8674(93)80068-p. [DOI] [PubMed] [Google Scholar]
  45. Lafaille J. J., Keere F. V., Hsu A. L., Baron J. L., Haas W., Raine C. S., Tonegawa S. Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J Exp Med. 1997 Jul 21;186(2):307–312. doi: 10.1084/jem.186.2.307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Ma S. W., Zhao D. L., Yin Z. Q., Mukherjee R., Singh B., Qin H. Y., Stiller C. R., Jevnikar A. M. Transgenic plants expressing autoantigens fed to mice to induce oral immune tolerance. Nat Med. 1997 Jul;3(7):793–796. doi: 10.1038/nm0797-793. [DOI] [PubMed] [Google Scholar]
  47. Marth T., Strober W., Kelsall B. L. High dose oral tolerance in ovalbumin TCR-transgenic mice: systemic neutralization of IL-12 augments TGF-beta secretion and T cell apoptosis. J Immunol. 1996 Sep 15;157(6):2348–2357. [PubMed] [Google Scholar]
  48. Mashimo H., Wu D. C., Podolsky D. K., Fishman M. C. Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science. 1996 Oct 11;274(5285):262–265. doi: 10.1126/science.274.5285.262. [DOI] [PubMed] [Google Scholar]
  49. McMenamin C., Pimm C., McKersey M., Holt P. G. Regulation of IgE responses to inhaled antigen in mice by antigen-specific gamma delta T cells. Science. 1994 Sep 23;265(5180):1869–1871. doi: 10.1126/science.7916481. [DOI] [PubMed] [Google Scholar]
  50. Metzler B., Wraith D. C. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. Int Immunol. 1993 Sep;5(9):1159–1165. doi: 10.1093/intimm/5.9.1159. [DOI] [PubMed] [Google Scholar]
  51. Meyer A. L., Benson J. M., Gienapp I. E., Cox K. L., Whitacre C. C. Suppression of murine chronic relapsing experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein. J Immunol. 1996 Nov 1;157(9):4230–4238. [PubMed] [Google Scholar]
  52. Miller A., Lider O., Roberts A. B., Sporn M. B., Weiner H. L. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):421–425. doi: 10.1073/pnas.89.1.421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Mowat A. M. Depletion of suppressor T cells by 2'-deoxyguanosine abrogates tolerance in mice fed ovalbumin and permits the induction of intestinal delayed-type hypersensitivity. Immunology. 1986 Jun;58(2):179–184. [PMC free article] [PubMed] [Google Scholar]
  54. Mowat A. M., Ferguson A. Hypersensitivity in the small intestinal mucosa. V. Induction of cell-mediated immunity to a dietary antigen. Clin Exp Immunol. 1981 Mar;43(3):574–582. [PMC free article] [PubMed] [Google Scholar]
  55. Mowat A. M., Garside P., Fitton L. A., Higley H. R., Carlino J. A. Regulatory activity of endogenous and exogenous transforming growth factor beta in experimental intestinal immunopathology. Growth Factors. 1996;13(1-2):75–85. doi: 10.3109/08977199609034568. [DOI] [PubMed] [Google Scholar]
  56. Mowat A. M., Viney J. L. The anatomical basis of intestinal immunity. Immunol Rev. 1997 Apr;156:145–166. doi: 10.1111/j.1600-065x.1997.tb00966.x. [DOI] [PubMed] [Google Scholar]
  57. Moyana T. N., Lalonde J. M. Carrageenan-induced intestinal injury in the rat--a model for inflammatory bowel disease. Ann Clin Lab Sci. 1990 Nov-Dec;20(6):420–426. [PubMed] [Google Scholar]
  58. Mueller D. L., Jenkins M. K. Molecular mechanisms underlying functional T-cell unresponsiveness. Curr Opin Immunol. 1995 Jun;7(3):375–381. doi: 10.1016/0952-7915(95)80113-8. [DOI] [PubMed] [Google Scholar]
  59. Nagler-Anderson C., Bober L. A., Robinson M. E., Siskind G. W., Thorbecke G. J. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci U S A. 1986 Oct;83(19):7443–7446. doi: 10.1073/pnas.83.19.7443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Neurath M. F., Fuss I., Kelsall B. L., Presky D. H., Waegell W., Strober W. Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J Exp Med. 1996 Jun 1;183(6):2605–2616. doi: 10.1084/jem.183.6.2605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Nussenblatt R. B., Caspi R. R., Mahdi R., Chan C. C., Roberge F., Lider O., Weiner H. L. Inhibition of S-antigen induced experimental autoimmune uveoretinitis by oral induction of tolerance with S-antigen. J Immunol. 1990 Mar 1;144(5):1689–1695. [PubMed] [Google Scholar]
  62. Nussenblatt R. B., Gery I., Weiner H. L., Ferris F. L., Shiloach J., Remaley N., Perry C., Caspi R. R., Hafler D. A., Foster C. S. Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial. Am J Ophthalmol. 1997 May;123(5):583–592. doi: 10.1016/s0002-9394(14)71070-0. [DOI] [PubMed] [Google Scholar]
  63. Nussenblatt R. B., Whitcup S. M., de Smet M. D., Caspi R. R., Kozhich A. T., Weiner H. L., Vistica B., Gery I. Intraocular inflammatory disease (uveitis) and the use of oral tolerance: a status report. Ann N Y Acad Sci. 1996 Feb 13;778:325–337. doi: 10.1111/j.1749-6632.1996.tb21140.x. [DOI] [PubMed] [Google Scholar]
  64. Okumura S., McIntosh K., Drachman D. B. Oral administration of acetylcholine receptor: effects on experimental myasthenia gravis. Ann Neurol. 1994 Nov;36(5):704–713. doi: 10.1002/ana.410360504. [DOI] [PubMed] [Google Scholar]
  65. Pape K. A., Khoruts A., Mondino A., Jenkins M. K. Inflammatory cytokines enhance the in vivo clonal expansion and differentiation of antigen-activated CD4+ T cells. J Immunol. 1997 Jul 15;159(2):591–598. [PubMed] [Google Scholar]
  66. Peterson K. E., Braley-Mullen H. Suppression of murine experimental autoimmune thyroiditis by oral administration of porcine thyroglobulin. Cell Immunol. 1995 Nov;166(1):123–130. doi: 10.1006/cimm.1995.0014. [DOI] [PubMed] [Google Scholar]
  67. Powrie F., Carlino J., Leach M. W., Mauze S., Coffman R. L. A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells. J Exp Med. 1996 Jun 1;183(6):2669–2674. doi: 10.1084/jem.183.6.2669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Powrie F. T cells in inflammatory bowel disease: protective and pathogenic roles. Immunity. 1995 Aug;3(2):171–174. doi: 10.1016/1074-7613(95)90086-1. [DOI] [PubMed] [Google Scholar]
  69. Rizzo L. V., Miller-Rivero N. E., Chan C. C., Wiggert B., Nussenblatt R. B., Caspi R. R. Interleukin-2 treatment potentiates induction of oral tolerance in a murine model of autoimmunity. J Clin Invest. 1994 Oct;94(4):1668–1672. doi: 10.1172/JCI117511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Roberts A. B., Sporn M. B. Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta). Growth Factors. 1993;8(1):1–9. doi: 10.3109/08977199309029129. [DOI] [PubMed] [Google Scholar]
  71. Rock K. L., Rothstein L., Fleischacker C., Gamble S. Inhibition of class I and class II MHC-restricted antigen presentation by cytotoxic T lymphocytes specific for an exogenous antigen. J Immunol. 1992 May 15;148(10):3028–3033. [PubMed] [Google Scholar]
  72. Sadlack B., Merz H., Schorle H., Schimpl A., Feller A. C., Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell. 1993 Oct 22;75(2):253–261. doi: 10.1016/0092-8674(93)80067-o. [DOI] [PubMed] [Google Scholar]
  73. Sayegh M. H., Khoury S. J., Hancock W. W., Weiner H. L., Carpenter C. B. Induction of immunity and oral tolerance with polymorphic class II major histocompatibility complex allopeptides in the rat. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7762–7766. doi: 10.1073/pnas.89.16.7762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Sayegh M. H., Zhang Z. J., Hancock W. W., Kwok C. A., Carpenter C. B., Weiner H. L. Down-regulation of the immune response to histocompatibility antigens and prevention of sensitization by skin allografts by orally administered alloantigen. Transplantation. 1992 Jan;53(1):163–166. doi: 10.1097/00007890-199201000-00033. [DOI] [PubMed] [Google Scholar]
  75. Schwartz R. H. Acquisition of immunologic self-tolerance. Cell. 1989 Jun 30;57(7):1073–1081. doi: 10.1016/0092-8674(89)90044-5. [DOI] [PubMed] [Google Scholar]
  76. Sieper J., Kary S., Sörensen H., Alten R., Eggens U., Hüge W., Hiepe F., Kühne A., Listing J., Ulbrich N. Oral type II collagen treatment in early rheumatoid arthritis. A double-blind, placebo-controlled, randomized trial. Arthritis Rheum. 1996 Jan;39(1):41–51. doi: 10.1002/art.1780390106. [DOI] [PubMed] [Google Scholar]
  77. Singh V. K., Kalra H. K., Yamaki K., Shinohara T. Suppression of experimental autoimmune uveitis in rats by the oral administration of the uveitopathogenic S-antigen fragment or a cross-reactive homologous peptide. Cell Immunol. 1992 Jan;139(1):81–90. doi: 10.1016/0008-8749(92)90101-t. [DOI] [PubMed] [Google Scholar]
  78. Staines N. A., Harper N., Ward F. J., Malmström V., Holmdahl R., Bansal S. Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope. Clin Exp Immunol. 1996 Mar;103(3):368–375. doi: 10.1111/j.1365-2249.1996.tb08289.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Strober W., Kelsall B., Fuss I., Marth T., Ludviksson B., Ehrhardt R., Neurath M. Reciprocal IFN-gamma and TGF-beta responses regulate the occurrence of mucosal inflammation. Immunol Today. 1997 Feb;18(2):61–64. doi: 10.1016/s0167-5699(97)01000-1. [DOI] [PubMed] [Google Scholar]
  80. Sun J. B., Rask C., Olsson T., Holmgren J., Czerkinsky C. Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7196–7201. doi: 10.1073/pnas.93.14.7196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Swarbrick E. T., Stokes C. R., Soothill J. F. Absorption of antigens after oral immunisation and the simultaneous induction of specific systemic tolerance. Gut. 1979 Feb;20(2):121–125. doi: 10.1136/gut.20.2.121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Symington F. W. Lymphotoxin, tumor necrosis factor, and gamma interferon are cytostatic for normal human keratinocytes. J Invest Dermatol. 1989 Jun;92(6):798–805. doi: 10.1111/1523-1747.ep12696816. [DOI] [PubMed] [Google Scholar]
  83. Thompson H. S., Harper N., Bevan D. J., Staines N. A. Suppression of collagen induced arthritis by oral administration of type II collagen: changes in immune and arthritic responses mediated by active peripheral suppression. Autoimmunity. 1993;16(3):189–199. doi: 10.3109/08916939308993327. [DOI] [PubMed] [Google Scholar]
  84. Thompson H. S., Staines N. A. Could specific oral tolerance be a therapy for autoimmune disease? Immunol Today. 1990 Nov;11(11):396–399. doi: 10.1016/0167-5699(90)90158-6. [DOI] [PubMed] [Google Scholar]
  85. Thompson H. S., Staines N. A. Gastric administration of type II collagen delays the onset and severity of collagen-induced arthritis in rats. Clin Exp Immunol. 1986 Jun;64(3):581–586. [PMC free article] [PubMed] [Google Scholar]
  86. Thompson S. J., Thompson H. S., Harper N., Day M. J., Coad A. J., Elson C. J., Staines N. A. Prevention of pristane-induced arthritis by the oral administration of type II collagen. Immunology. 1993 May;79(1):152–157. [PMC free article] [PubMed] [Google Scholar]
  87. Thurau S. R., Chan C. C., Nussenblatt R. B., Caspi R. R. Oral tolerance in a murine model of relapsing experimental autoimmune uveoretinitis (EAU): induction of protective tolerance in primed animals. Clin Exp Immunol. 1997 Aug;109(2):370–376. doi: 10.1046/j.1365-2249.1997.4571356.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Trentham D. E., Dynesius-Trentham R. A., Orav E. J., Combitchi D., Lorenzo C., Sewell K. L., Hafler D. A., Weiner H. L. Effects of oral administration of type II collagen on rheumatoid arthritis. Science. 1993 Sep 24;261(5129):1727–1730. doi: 10.1126/science.8378772. [DOI] [PubMed] [Google Scholar]
  89. Van Houten N., Blake S. F. Direct measurement of anergy of antigen-specific T cells following oral tolerance induction. J Immunol. 1996 Aug 15;157(4):1337–1341. [PubMed] [Google Scholar]
  90. Vistica B. P., Chanaud N. P., 3rd, Felix N., Caspi R. R., Rizzo L. V., Nussenblatt R. B., Gery I. CD8 T-cells are not essential for the induction of "low-dose" oral tolerance. Clin Immunol Immunopathol. 1996 Feb;78(2):196–202. doi: 10.1006/clin.1996.0029. [DOI] [PubMed] [Google Scholar]
  91. Vives J., Parks D. E., Weigle W. O. Immunologic unresponsiveness after gastric administration of human gamma-globulin: antigen requirements and cellular parameters. J Immunol. 1980 Oct;125(4):1811–1816. [PubMed] [Google Scholar]
  92. Waldo F. B., van den Wall Bake A. W., Mestecky J., Husby S. Suppression of the immune response by nasal immunization. Clin Immunol Immunopathol. 1994 Jul;72(1):30–34. doi: 10.1006/clin.1994.1103. [DOI] [PubMed] [Google Scholar]
  93. Wang Z. Y., He B., Qiao J., Link H. Suppression of experimental autoimmune myasthenia gravis and experimental allergic encephalomyelitis by oral administration of acetylcholine receptor and myelin basic protein: double tolerance. J Neuroimmunol. 1995 Dec;63(1):79–86. doi: 10.1016/0165-5728(95)00136-0. [DOI] [PubMed] [Google Scholar]
  94. Wang Z. Y., Qiao J., Link H. Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor. J Neuroimmunol. 1993 May;44(2):209–214. doi: 10.1016/0165-5728(93)90045-z. [DOI] [PubMed] [Google Scholar]
  95. Weiner H. L., Mackin G. A., Matsui M., Orav E. J., Khoury S. J., Dawson D. M., Hafler D. A. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science. 1993 Feb 26;259(5099):1321–1324. doi: 10.1126/science.7680493. [DOI] [PubMed] [Google Scholar]
  96. Weiner H. L. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today. 1997 Jul;18(7):335–343. doi: 10.1016/s0167-5699(97)01053-0. [DOI] [PubMed] [Google Scholar]
  97. Whitacre C. C., Gienapp I. E., Orosz C. G., Bitar D. M. Oral tolerance in experimental autoimmune encephalomyelitis. III. Evidence for clonal anergy. J Immunol. 1991 Oct 1;147(7):2155–2163. [PubMed] [Google Scholar]
  98. Wildner G., Thurau S. R. Orally induced bystander suppression in experimental autoimmune uveoretinitis occurs only in the periphery and not in the eye. Eur J Immunol. 1995 May;25(5):1292–1297. doi: 10.1002/eji.1830250524. [DOI] [PubMed] [Google Scholar]
  99. Wolvers D. A., van der Cammen M. J., Kraal G. Mucosal tolerance is associated with, but independent of, up-regulation Th2 responses. Immunology. 1997 Nov;92(3):328–333. doi: 10.1046/j.1365-2567.1997.00356.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  100. Yoshino S., Quattrocchi E., Weiner H. L. Suppression of antigen-induced arthritis in Lewis rats by oral administration of type II collagen. Arthritis Rheum. 1995 Aug;38(8):1092–1096. doi: 10.1002/art.1780380811. [DOI] [PubMed] [Google Scholar]
  101. Zhang Z. J., Davidson L., Eisenbarth G., Weiner H. L. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10252–10256. doi: 10.1073/pnas.88.22.10252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  102. Zhang Z. Y., Lee C. S., Lider O., Weiner H. L. Suppression of adjuvant arthritis in Lewis rats by oral administration of type II collagen. J Immunol. 1990 Oct 15;145(8):2489–2493. [PubMed] [Google Scholar]
  103. von Herrath M. G., Dyrberg T., Oldstone M. B. Oral insulin treatment suppresses virus-induced antigen-specific destruction of beta cells and prevents autoimmune diabetes in transgenic mice. J Clin Invest. 1996 Sep 15;98(6):1324–1331. doi: 10.1172/JCI118919. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES